Clinical Trial
March 23, 2026
Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes
If you have type 2 diabetes, you may notice that you
Read original source
🔔
Get Diabetes Alerts
Free weekly updates from NIH, CDC & FDA when new research drops. No spam. Unsubscribe anytime.
Diabetes by the Numbers
37M
Americans with diabetes
1 in 5
don't know they have it
327B
annual U.S. cost ($)
90%
are type 2
Myth vs. Fact
❌ Myth
"Diabetes is caused by eating too much sugar."
👆 Tap to see the truth
✅ Fact
Type 2 diabetes is caused by insulin resistance — a complex combination of genetics, weight, activity level, and metabolic factors. Sugar is one piece, not the whole story.
👆 Tap to flip back
❌ Myth
"People with diabetes can't eat carbs."
👆 Tap to see the truth
✅ Fact
Carbs are fine in moderation. The type (whole grains, legumes) and quantity matter more than total elimination. A dietitian can help personalize your plan.
👆 Tap to flip back
❌ Myth
"Insulin means you've 'failed' at managing your diabetes."
👆 Tap to see the truth
✅ Fact
Diabetes is progressive for many people. Needing insulin reflects disease progression, not personal failure. It's a tool, not a punishment.
👆 Tap to flip back
❌ Myth
"Thin people don't get type 2 diabetes."
👆 Tap to see the truth
✅ Fact
Up to 20% of type 2 diagnoses occur in people with normal BMI. "Metabolically unhealthy" body composition can exist at any weight.
👆 Tap to flip back
Did You Know?
A 5–7% weight loss reduces type 2 diabetes risk by 58% in high-risk individuals.
GLP-1 medications like Ozempic were originally developed for diabetes — not weight loss.
The A1C test measures average blood sugar over 3 months, not just today's level.
Regular walking (150 min/week) is one of the most evidence-backed interventions for blood sugar control.
Sleep deprivation raises blood glucose levels — poor sleep and diabetes are tightly linked.
Breakdown by Type
90%
Type
90% Type 2
5% Type 1
5% Other types
Disease Progression
A1C 5.7–6.4%
Pre-diabetes
Blood sugar elevated but not yet at diabetes level. 70% of pre-diabetics progress to type 2 if untreated.
A1C ≥6.5%
Diagnosis
Often found incidentally on a routine blood test. Many people have had elevated sugar for years before diagnosis.
Year 1–3
Early Management
Lifestyle + metformin. A1C target: under 7% for most. Monitoring for early complications begins.
Year 5–10+
Long-term
With good control, most avoid serious complications. Without control: nerve damage, kidney disease, vision loss.
You're In Good Company
↔ scroll to see moreDiabetes is a condition that touches people at every level of public life. Their stories help normalize the conversation.
Tom Hanks
Type 2 Diabetes
"I have Type 2 diabetes." — announced live on Late Show, 2013
Read their story →
Paula Deen
Type 2 Diabetes
Paula Deen disclosed her Type 2 diagnosis in 2012 after managing it privately for three years.
Read their story →
Drew Carey
Type 2 Diabetes (reversed)
Drew Carey reversed his Type 2 diabetes through weight loss — and has been medication-free since.
Read their story →
Patti LaBelle
Type 2 Diabetes
Grammy winner Patti LaBelle has been a leading voice in diabetes awareness for over two decades.
Read their story →
All information sourced from public statements and verified media reports. My Sugar Pill does not represent or speak for any individual.
Clinical Trial
March 23, 2026
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
with takeaway:* Talk to your doctor if you have a family history or are at
Read original source
Clinical Trial
March 23, 2026
Surveillance of Pancreatic Health After Diabetes Diagnosis
If you have recently been diagnosed with type 2 diabetes, researchers are working on
Read original source
FDA
November 1, 2025
Biosimilar Insulin Guide 2026: Cheaper Alternatives to Lantus, Humalog, and NovoLog
Insulin prices in the United States have historically been among the highest in the world. Over the past several years, biosimilar insulins have entered the market, creating significantly cheaper alternatives to brand-name products. Here's what every person on insulin needs to know. **What is a biosimilar insulin?** A biosimilar is a biological product that is highly similar to an already-approved reference product (the "brand-name") with no clinically meaningful differences in safety, purity, or potency. Biosimilar insulins have gone through rigorous FDA review. **Key biosimilars now available:** **Basaglar (insulin glargine):** Made by Eli Lilly; similar to Lantus (Sanofi). FDA approved 2015. Same long-acting profile as Lantus. Cost: ~$75/vial (vs. $300+ for Lantus brand). Available at most pharmacies. **Rezvoglar (insulin glargine-aglr):** Made by Eli Lilly; interchangeable with Lantus (FDA-designated as interchangeable, meaning the pharmacist can substitute it for Lantus without a new prescription). Cost: as low as $35/vial through Lilly's program. **Semglee (insulin glargine-yfgn):** Made by Viatris. FDA interchangeable with Lantus. Priced significantly below brand Lantus. Available OTC at Walmart as ReliOn Glargine at $80–$90/vial. **Civica Insulin (nonprofit):** Civica Rx is producing biosimilar versions of glargine, aspart, and lispro at a target price of $35/vial or less. Partnership with Mark Cuban's Cost Plus Drugs — available now. **Walmart ReliOn Insulins (no prescription required):** - ReliOn NovoLog (aspart): ~$73/vial OTC - ReliOn Lantus (glargine): ~$80/vial OTC - ReliOn Humalog (lispro): ~$73/vial OTC - Human insulin (NPH, Regular): $25/vial OTC — the original low-cost insulin option **How to switch:** Do NOT switch insulin types or brands without consulting your doctor or diabetes educator. Doses may need adjustment. However, switching between brand-name glargine and interchangeable biosimilars is generally straightforward — your pharmacist can often do this automatically. **Key resource:** NovoCare and Lilly Insulin Value Programs provide brand-name insulin for as low as $35/month regardless of insurance status for qualifying patients.
Read original source
NIH
December 1, 2025
Drug Savings Programs for Diabetes Medications: Copay Cards, PAPs, and How to Use Them
Brand-name diabetes medications — Ozempic, Mounjaro, Jardiance, Trulicity, Farxiga — can cost $600–$1,100/month at list price. Most insured patients pay far less. And for those without insurance or on Medicare, manufacturer programs can dramatically reduce out-of-pocket costs. Here's a practical guide. **Manufacturer Copay Cards (commercial insurance only — NOT Medicare):** These cards reduce what you pay at the pharmacy. Typically: $0–$25/month for qualifying patients with commercial (employer or marketplace) insurance. | Drug | Manufacturer | Program Name | Cost with Card | |------|-------------|--------------|----------------| | Ozempic | Novo Nordisk | NovoCare | $0 for 2 years (qualifying new patients) | | Mounjaro | Eli Lilly | Lilly Insulin Value | $35/month cap | | Trulicity | Eli Lilly | Lilly Cares | $0–$25/month | | Jardiance | Boehringer Ingelheim | BI Cares | $0 first fill, then $10/month | | Farxiga | AstraZeneca | AZ&ME | Free for eligible uninsured patients | To get these cards: Search "[drug name] savings card" or visit the manufacturer's website. You get a card or code to give to the pharmacy. **Patient Assistance Programs (uninsured or Medicare patients):** These provide free or heavily discounted medications for patients who meet income requirements. - Novo Nordisk Patient Assistance Program: Free Ozempic, Victoza, Rybelsus for qualifying uninsured patients (income below ~$50,000 for single person) - Lilly Cares: Free Mounjaro, Trulicity, Basaglar for uninsured/underinsured patients - AZ&ME: Free Farxiga, Bydureon for eligible patients - NeedyMeds.org: Database of all pharmaceutical patient assistance programs — start here **Medicare and GLP-1s:** Medicare Part D began covering GLP-1 drugs for cardiovascular risk reduction in 2024. Coverage for weight loss alone (without a diabetes or CV indication) may still require prior authorization. The Inflation Reduction Act caps Medicare Part D out-of-pocket at $2,000/year (2025 onward). **Goodrx and discount programs:** GoodRx doesn't work for GLP-1s at list price — too expensive. But it works well for generic medications (metformin, glipizide, insulin NPH) where prices are already low. Use Mark Cuban's Cost Plus Drugs (costplusdrugs.com) for generic diabetes medications — sometimes 80–90% cheaper than retail. **Insulin-specific: $35 cap law:** The Inflation Reduction Act capped insulin cost-sharing for Medicare Part D enrollees at $35/month per insulin (2023+). Some states have similar caps for commercial insurance.
Read original source
NIH
October 1, 2025
Diabetic Retinopathy Screening: What It Is, When to Go, and What Happens During the Exam
Diabetic retinopathy is the leading cause of new blindness in working-age adults in the United States. About 1 in 3 people with diabetes have some form of retinopathy — but in early stages, it causes no symptoms. That's why routine screening is so critical. **What is diabetic retinopathy?** High blood sugar damages the tiny blood vessels in the retina (the light-sensitive layer at the back of the eye). Blood vessels can leak, swell, or grow abnormally. In advanced stages (proliferative retinopathy), new fragile blood vessels grow and can bleed into the eye, causing vision loss or detachment. **Stages:** - Non-proliferative diabetic retinopathy (NPDR): Early stage. Blood vessels leak fluid or blood. May cause blurred vision; often no symptoms. - Diabetic macular edema (DME): Fluid accumulates in the macula (center of the retina, responsible for sharp vision). Causes blurry or wavy central vision. Can occur at any stage. - Proliferative diabetic retinopathy (PDR): Advanced stage. Abnormal new blood vessels grow on the retina or optic nerve. High risk of vision loss without treatment. **How often to screen:** - Type 2 diabetes: Comprehensive dilated eye exam at diagnosis, then annually - If no retinopathy and A1C is well-controlled: every 1–2 years may be appropriate per your eye doctor - Pregnancy with diabetes: Before pregnancy or in the first trimester, then every trimester during pregnancy, and 1 year postpartum **What happens during a dilated eye exam:** Drops widen (dilate) your pupils so the eye doctor can see the entire retina clearly. The exam takes about 30–40 minutes. You'll have blurred vision for several hours afterward — bring sunglasses and someone to drive you home. **Treatment if retinopathy is found:** - Anti-VEGF injections (ranibizumab/Lucentis, aflibercept/Eylea, bevacizumab/Avastin): First-line for DME and PDR. Monthly injections into the eye slow vision loss and often improve it. - Laser treatment (photocoagulation): Seals leaking vessels; less commonly used since anti-VEGF became available - Vitrectomy: Surgery to remove blood from the vitreous (gel inside the eye) in severe PDR **Prevention:** Blood sugar control is the most powerful intervention. The UKPDS trial showed that every 1% reduction in A1C corresponds to a 35% reduction in retinopathy risk. Don't skip your annual eye exams.
Read original source
NIH
September 1, 2025
Diabetic Neuropathy: Symptoms, Types, and Managing Nerve Damage
Diabetic neuropathy is nerve damage caused by prolonged high blood sugar. It affects about 50% of people with diabetes and is the most common long-term complication. The good news: it's largely preventable with good blood sugar control — and there are effective treatments for symptoms once nerve damage has occurred. **Types of diabetic neuropathy:** **Peripheral neuropathy (most common):** Affects the feet and legs first (then hands and arms). Symptoms: numbness, tingling, burning, or stabbing pain — usually worse at night. Loss of sensation is dangerous because injuries on the feet go unnoticed and can progress to infection or ulcers. **Autonomic neuropathy:** Damages the nerves that control involuntary body functions. Can affect the heart (resting fast pulse, inability to increase heart rate during exercise), digestive tract (gastroparesis — delayed stomach emptying causing nausea, unpredictable blood sugar), bladder (incomplete emptying, infections), and sexual function. **Proximal neuropathy (diabetic amyotrophy):** Sudden pain in hips, thighs, or buttocks; muscle weakness. More common in older adults. Often partially reversible with blood sugar improvement. **Focal neuropathy:** Sudden nerve damage causing pain or weakness in a specific area (face, torso, leg). Usually temporary. **Prevention:** The most powerful prevention is keeping blood sugar in target range. The DCCT trial showed intensive blood sugar control reduced neuropathy risk by 60% in type 1 diabetes. Controlling blood pressure and not smoking also matter. **Treatment options:** - Pain relief: Duloxetine (Cymbalta, first-line FDA-approved), pregabalin (Lyrica, FDA-approved), gabapentin (off-label but widely used), tricyclics (amitriptyline, low-dose), topical capsaicin cream, lidocaine patches - Blood sugar control: Improving A1C can slow progression and, in early stages, partially reverse neuropathy - Foot care: Daily foot inspections, proper footwear, annual foot exams — the cornerstones of preventing ulcers **When to see your doctor immediately:** An open sore, wound, or ulcer on the foot that isn't healing within a week. Unexplained pain, swelling, or redness in the foot. Any infection on a foot with reduced sensation.
Read original source
NIH
August 1, 2025
Hypoglycemia Prevention Guide for Type 2 Diabetes: Symptoms, Causes, and What to Do
Hypoglycemia (low blood sugar) means your glucose has dropped below 70 mg/dL. It's the most dangerous acute complication of diabetes treatment — particularly in people using insulin or sulfonylureas. Understanding your risk, recognizing symptoms early, and knowing how to treat it can prevent serious injury. **Who is at risk:** Hypoglycemia is most common in people using insulin or sulfonylureas (glipizide, glyburide, glimepiride). GLP-1s, SGLT2s, DPP-4s, and metformin do NOT cause hypoglycemia on their own — only when combined with insulin or sulfonylureas. **Symptoms by severity:** - Mild (70–54 mg/dL): Shakiness, sweating, rapid heartbeat, hunger, anxiety, pale skin, blurred vision - Moderate (54–40 mg/dL): Confusion, difficulty concentrating, slurred speech, coordination problems - Severe (below 40 mg/dL): Loss of consciousness, seizure, requiring emergency assistance **Common triggers:** Skipping or delaying a meal; exercising more than usual; taking too much insulin; drinking alcohol (suppresses liver glucose release); kidney disease (slows insulin clearance, increasing hypoglycemia risk) **The 15-15 rule for mild hypoglycemia:** If you're conscious and can swallow: eat 15 grams of fast-acting carbs. Wait 15 minutes. Recheck glucose. If still below 70, repeat. Examples of 15g fast-acting carbs: 4 glucose tablets, 4 oz (half cup) of juice or regular soda, 1 tablespoon of honey. **Glucagon emergency kits:** If someone is unconscious or can't swallow safely, they need glucagon — a hormone that raises blood sugar quickly. Options: Gvoke auto-injector (simple, one-step), Baqsimi nasal powder (no injection required), Glucagen kit (traditional needle-and-vial). Medicare and most insurance cover one glucagon kit. All people using insulin should have one at home. **Prevention strategies:** Use a CGM to catch lows before they become dangerous. Don't skip meals. Reduce sulfonylurea doses if you're losing weight (lower body weight = more drug effect). Talk to your doctor about switching from sulfonylureas to GLP-1s or SGLT2s, which don't cause hypoglycemia. Exercise with a snack on hand.
Read original source
CDC
November 1, 2025
How to Lower Your A1C: Evidence-Based Strategies That Actually Work
Your A1C test reflects your average blood sugar for the past 2–3 months. The American Diabetes Association (ADA) recommends an A1C below 7% for most adults with type 2 diabetes — below 8% for older adults with other health conditions. Here's what the evidence says actually moves the number. **What one A1C point means:** Each 1% reduction in A1C reduces the risk of diabetic eye disease by 35%, kidney disease by 25%, nerve damage by 25%, and heart disease by 14–16%. Getting from 8% to 7% is not just a number on paper — it's a meaningful reduction in complications. **Lifestyle changes that lower A1C:** - **Low-carbohydrate diet:** The strongest dietary intervention for blood sugar. Reducing total carbs from 250g to 100–130g/day can lower A1C by 0.5–1.5% within 3–6 months. You don't need to go keto — just cutting white bread, pasta, rice, sweets, and sugary drinks makes a significant difference. - **Exercise:** 150 minutes/week of moderate aerobic activity (walking briskly, cycling, swimming) lowers A1C by ~0.5–0.7%. Resistance training adds another 0.3–0.5%. The combination is more powerful than either alone. - **Weight loss:** Every 1 kg lost corresponds to roughly a 0.1% A1C reduction. Losing 10–15 lbs can move A1C by 0.5–1.0%. - **Sleep improvement:** Poor sleep (under 6 hours or sleep apnea) raises blood sugar. Treating sleep apnea alone has lowered A1C by 0.4–0.5% in some studies. **Medications ranked by A1C-lowering power (approximate):** 1. Mounjaro (tirzepatide): 2.0–2.5% 2. Ozempic 2 mg (semaglutide): 1.5–1.8% 3. GLP-1s generally: 1.0–1.5% 4. SGLT2 inhibitors: 0.5–1.0% 5. DPP-4 inhibitors: 0.5–0.8% 6. Metformin: 1.0–1.5% 7. Sulfonylureas: 1.0–1.5% (but cause weight gain and hypoglycemia) 8. Insulin: variable; can lower A1C by 1–3%+ depending on regimen **Practical tips:** Test more frequently (CGM or finger sticks) — people who check more often make better decisions and have lower A1C. Log meals, at least briefly, to find your personal blood sugar triggers. Take medications consistently — A1C variability between doses is a hidden driver of elevated average.
Read original source
NIH
December 1, 2025
Insulin Pump Comparison 2026: Medtronic vs. Tandem vs. Omnipod — Which Is Right for You?
If you're considering an insulin pump for type 2 diabetes, the three main systems are Medtronic MiniMed, Tandem t:slim X2, and Insulet Omnipod. Each has different strengths. Here's how they compare on the factors that matter most for everyday use. **Medtronic MiniMed 780G:** - Type: Tubed pump - Automation: Advanced hybrid closed-loop ("auto mode") — automatically adjusts basal AND corrects high glucose every 5 minutes - CGM: Integrates with Medtronic Guardian 4 sensor (built-in, no separate CGM needed) - Unique feature: Auto-correction boluses (actively corrects highs without user input) - Target glucose: Adjustable 100–180 mg/dL - Best for: Patients who want the most automated experience and prefer an all-in-one Medtronic ecosystem - Downside: Requires use of Medtronic's own CGM (can't use Dexcom or Libre) **Tandem t:slim X2 with Control-IQ:** - Type: Tubed pump - Automation: Hybrid closed-loop — adjusts basal rate + delivers correction boluses when glucose is high; suspends for lows - CGM: Integrates with Dexcom G6 (current) and G7 (rolling out) - Unique feature: Software updatable via computer at home — future algorithm improvements without a new pump - Target glucose: ~112 mg/dL (sleep mode targets lower, ~100 mg/dL) - Best for: Dexcom users who want reliable closed-loop automation with a proven track record (InControl-IQ is one of the most-studied AID algorithms) - Downside: Tubing can be inconvenient for some activities **Omnipod 5:** - Type: Tubeless (patch) pump - Automation: Hybrid closed-loop — adjusts basal; does not currently deliver automated correction boluses - CGM: Integrates with Dexcom G6 (G7 integration in progress) - Unique feature: No tubing. Waterproof. Pod worn directly on body (arms, abdomen, back of arm) - Target glucose: Adjustable 110–150 mg/dL - Best for: Active patients, swimmers, those who find tubing inconvenient, or patients new to pumping who want an easier learning curve - Downside: Each pod costs more per unit than tubed pump cartridges; less aggressive automated correction than MiniMed 780G **Cost summary:** All three pumps: $4,000–$7,000 upfront device cost + $200–$600/month supplies. Most are covered by Medicare Part B and commercial insurance for qualifying patients. **How to choose:** Talk to your endocrinologist and ideally your diabetes educator (CDE). Most pump companies offer trial programs or demos. Tandem is popular among Dexcom users; Omnipod suits active and needle-averse patients; Medtronic appeals to those wanting maximum automation in one ecosystem.
Read original source
FDA
September 1, 2025
FreeStyle Libre 3 Guide 2026: Accuracy, Comfort, App Features, and Cost
The FreeStyle Libre 3 is Abbott's flagship continuous glucose monitor and the smallest, thinnest CGM sensor available today. It's the CGM of choice for millions of diabetes patients worldwide — and in 2025, it earned expanded FDA clearance. Here's what you need to know. **The sensor:** Smaller than a US penny. Applied to the upper arm with a one-press applicator. No calibration required. 14-day wear. The Libre 3 sensor streams glucose readings to your phone automatically every minute — unlike older Libre models that required you to scan the sensor with your phone. It's the only CGM with a 1-minute reading interval. **Accuracy:** MARD of 7.9% in clinical trials — among the best available. FDA-cleared for insulin dosing decisions without confirmatory finger sticks. **App features:** The FreeStyle LibreLink app shows your current glucose, 8-hour trend arrow, last 12-hour graph, and time-in-range statistics. The LibreLinkUp app lets family members follow your readings in real-time. LibreView for HCP is your doctor's dashboard for reviewing glucose patterns. **FreeStyle Libre 3 vs. Dexcom G7:** - Sensor size: Libre 3 is significantly smaller and lower-profile - Reading interval: Libre 3 updates every 1 min; G7 every 5 min - Wear time: Libre 3 = 14 days; G7 = 10 days - Warmup: Libre 3 = 60 min; G7 = 30 min - Insulin pump integration: G7 integrates with Tandem t:slim; Libre 3 is standalone (no closed-loop pump integration currently) - OTC option: Dexcom Stelo is available OTC; Abbott's Lingo is available OTC (type 2, non-insulin) **Cost:** With prescription and commercial insurance: often $25–$75/month. Medicare Part B covers CGMs for insulin users. Without insurance: ~$75–$130/month (cheaper than G7 in most markets). Abbott's Libre 3 myAbbott savings program offers discounts. **Getting started:** Talk to your doctor about whether a CGM is right for you. Most type 2 patients on insulin, or with frequent hypoglycemia, are strong candidates. Some insurance plans now cover CGMs for type 2 patients not on insulin if A1C is above 8%.
Read original source
FDA
October 15, 2025
Dexcom G7 CGM Review 2026: How It Works, Setup, Accuracy, and Insurance Coverage
The Dexcom G7 is currently the most widely used continuous glucose monitor (CGM) in the United States. A CGM measures your blood sugar every 5 minutes, all day and all night, without finger sticks — and displays readings on your phone or a dedicated receiver. Here's everything you need to know about the G7. **What it is:** A small sensor (about the size of a quarter) worn on the upper arm or abdomen. A hair-thin filament sits just under the skin and measures glucose in the fluid between cells (interstitial fluid). It transmits readings to your phone via Bluetooth every 5 minutes. **The G7 vs. G6 improvements:** 60% smaller sensor. Integrated transmitter (all-in-one, no separate transmitter to recharge). 30-minute warmup (vs. 2 hours for G6). 10-day wear. Simultaneous old/new sensor overlap for seamless switchovers. **Accuracy:** The G7 achieved a MARD (mean absolute relative difference) of 8.2% in clinical trials — excellent performance. For context, a MARD under 10% is considered accurate for insulin dosing decisions. The G7 is FDA-cleared for non-adjunctive use, meaning you can make insulin dosing decisions based on CGM readings alone without a confirmatory finger stick (except when symptoms don't match the reading). **Alerts and alarms:** Customizable high and low glucose alarms. Urgent low alarm (below 55 mg/dL) cannot be silenced — by design. Share readings with up to 10 followers via Dexcom Follow app. Integration with Dexcom Clarity app for trend analysis. **Integration:** Works with Tandem t:slim X2 (automated closed-loop insulin delivery), Apple Health, Google Fit. G7 Stelo version available OTC without prescription for type 2 patients not on insulin. **Cost and insurance:** For people with type 2 diabetes on insulin: typically covered by Medicare Part B (80% coverage after deductible) and most commercial insurance. Out-of-pocket: ~$300–$400/month without insurance. With Medicare or insurance: often $50–$100/month or less. The Dexcom Stelo (OTC, no prescription) costs ~$99/month for type 2 patients not on insulin. **Getting started:** Ask your doctor for a prescription. Dexcom has a free starter kit program — start at dexcom.com/try.
Read original source
NIH
July 15, 2025
Insulin Pump vs. Daily Injections for Type 2 Diabetes: Pros, Cons, and Who Benefits
For type 2 diabetes patients using insulin, there are two main delivery options: multiple daily injections (MDI) using syringes or pens, and continuous subcutaneous insulin infusion (CSII) using an insulin pump. Here's a plain comparison to help you understand both options. **How multiple daily injections (MDI) work:** You take one or two daily injections of long-acting (basal) insulin for background coverage, plus rapid-acting insulin before each meal. Most people on MDI use a pen — either a disposable prefilled pen or a reusable pen with a cartridge. Common regimen: glargine (Lantus) at bedtime + lispro (Humalog) before meals. **Pros of MDI:** No device to wear. Simpler to start. Lower cost (pens + vials vs. pump + supplies). Works well for patients with predictable schedules. Covered by all insurance plans. **How insulin pumps work:** A small device (roughly pager-sized) worn on your body delivers insulin continuously through a thin tube (or, in tubeless pumps like the Omnipod, directly via a pod). You program a "basal rate" that runs 24/7, plus press a button to deliver a "bolus" before meals. Rapid-acting insulin only — no long-acting needed. **Pros of insulin pumps:** Extremely precise dosing. Easier to adjust for exercise, illness, meals that change. Better mimics normal pancreatic function. Some pumps integrate with CGMs (continuous glucose monitors) for "closed-loop" or "hybrid closed-loop" control — automatically adjusting basal insulin based on real-time glucose readings. Less hypoglycemia overnight in well-managed pump users. **Pumps used in type 2 diabetes:** Medtronic MiniMed, Tandem t:slim X2 (integrates with Dexcom G6/G7), Omnipod 5 (tubeless, integrates with Dexcom G6). The Omnipod 5 automated insulin delivery system is increasingly used in type 2 patients. **Who benefits most from a pump:** Type 2 patients with significant A1C instability despite MDI, frequent hypoglycemia, irregular schedules (shift workers, frequent travelers), or who want tighter control. **Cost:** Pumps cost $4,000–$7,000 upfront + $300–$500/month in supplies. Most insurance covers pumps for qualifying patients. MDI supplies (pens + strips) typically run $100–$300/month depending on insulin type. **Bottom line:** MDI is the standard, works well for most type 2 patients, and is simpler to manage. Pumps offer precision and automation for patients who want tighter control or struggle with MDI regimens. Discuss with your endocrinologist whether a pump makes sense for your situation.
Read original source
NIH
November 1, 2025
GLP-1 vs. SGLT2 vs. DPP-4 Inhibitors: Which Diabetes Drug Class Is Right for You?
After metformin, there are three major drug classes your doctor might add to your diabetes treatment: GLP-1 receptor agonists (like Ozempic, Mounjaro, Trulicity), SGLT2 inhibitors (like Jardiance, Farxiga), and DPP-4 inhibitors (like Januvia, Tradjenta, Onglyza). Each works differently and benefits different patients. **GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide):** - Mechanism: Mimic gut hormones to boost insulin release, suppress glucagon, slow digestion - A1C reduction: 1.0–2.5% (highest of the three classes) - Weight loss: 5–25+ lbs (significant) - Heart protection: Proven in multiple trials (Ozempic, Trulicity, others) - Kidney protection: Emerging data - Side effects: Nausea, vomiting, diarrhea (usually transient) - Form: Weekly or daily injection (oral semaglutide Rybelsus available) - Best for: Patients who need maximum A1C reduction, significant weight loss, and/or have cardiovascular disease **SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin):** - Mechanism: Block kidney glucose reabsorption → glucose excreted in urine - A1C reduction: 0.5–1.0% (moderate) - Weight loss: 3–6 lbs (modest) - Heart protection: Excellent (especially heart failure — reduces hospitalization 25–35%) - Kidney protection: Excellent — slows CKD progression significantly - Side effects: Yeast infections, UTIs, rare DKA risk - Form: Oral pill (once daily) - Best for: Patients with heart failure, chronic kidney disease, or who prefer pills **DPP-4 inhibitors (sitagliptin/Januvia, linagliptin/Tradjenta, saxagliptin/Onglyza):** - Mechanism: Block the enzyme that breaks down natural GLP-1, extending its effect - A1C reduction: 0.5–0.8% (modest) - Weight loss: Neutral (no weight change) - Heart protection: Neutral (no benefit, no harm in trials) - Kidney protection: Minimal - Side effects: Very well tolerated; rare risk of pancreatitis and joint pain - Form: Oral pill (once daily) - Best for: Patients who need moderate A1C improvement with minimal side effects, or who can't tolerate GLP-1 injections and don't have heart failure/CKD **Quick decision guide:** - Need to lose weight AND lower A1C significantly? → GLP-1 - Have heart failure or CKD? → SGLT2 (possibly add GLP-1 if tolerated) - Need mild A1C improvement with minimal side effects? → DPP-4 - Many patients benefit from combining GLP-1 + SGLT2 for additive effects on all three goals.
Read original source
NIH
August 15, 2025
Types of Insulin for Type 2 Diabetes: Rapid, Long-Acting, and Everything in Between
If lifestyle changes and oral medications haven't been enough to control your blood sugar, insulin may be the next step. Many people feel anxious when their doctor first mentions insulin — but modern insulin therapy is safer and easier than ever. Here's a plain-language guide to the different types. **Rapid-acting insulins** (mealtime): These kick in within 10–15 minutes and peak at about 1–2 hours. You take them right before eating to cover the glucose from that meal. Examples: insulin lispro (Humalog), insulin aspart (NovoLog/NovoRapid), insulin glulisine (Apidra), and ultra-rapid formulas like Fiasp and Lyumjev. **Short-acting insulin** (Regular insulin): Slower than rapid-acting — onset 30–60 minutes, peak 2–4 hours. Usually taken 30 minutes before meals. Regular insulin is also the form used in IV drips in hospitals. Examples: Humulin R, Novolin R. Mostly replaced by rapid-acting analogs in outpatient settings. **Intermediate-acting insulin (NPH):** Peaks at 4–12 hours, lasts 14–24 hours. Older option, less predictable. Still used in combination products. Examples: Humulin N, Novolin N. **Long-acting insulins** (basal): One or two injections per day, no peak, works steadily over 20–42 hours. These are the most common starting point for type 2 diabetes insulin therapy. Examples: insulin glargine (Lantus, Basaglar, Toujeo), insulin detemir (Levemir), insulin degludec (Tresiba). Long-acting insulin is often added at bedtime to control morning fasting blood sugar. **Premixed insulins:** A fixed combination of rapid + intermediate in one pen. Convenient but less flexible. Example: NovoLog Mix 70/30 (70% NPH + 30% aspart). **Starting insulin in type 2 diabetes:** Most type 2 patients start with a single bedtime dose of long-acting insulin (10 units or 0.1–0.2 units/kg). The dose is adjusted upward until fasting blood sugar is in target range (typically 80–130 mg/dL). This is called "basal insulin therapy" and often dramatically improves A1C without requiring mealtime shots. **Cost:** Biosimilar and authorized generic insulins have dramatically reduced costs. Insulin glargine (Basaglar, Rezvoglar) can be under $50/vial. Walmart's ReliOn brand NPH and Regular: $25/vial over the counter (no prescription required in most US states). See the insulin biosimilar article for full details.
Read original source
NIH
July 1, 2025
Metformin XR vs. Regular Metformin: What's the Difference?
Metformin is the world's most prescribed diabetes medication and the standard first-line treatment for type 2 diabetes. It comes in two forms: immediate-release (regular metformin) and extended-release (Metformin XR, also called metformin ER). Here's what the difference means for you. **How metformin works:** It reduces the amount of glucose your liver releases into your bloodstream, makes your cells more sensitive to insulin, and slightly reduces glucose absorption from food. It does NOT cause hypoglycemia on its own, doesn't cause weight gain, and costs pennies per pill in generic form. **Regular metformin (immediate-release):** Releases quickly in the digestive tract. Standard doses: 500 mg or 850 mg, taken 2–3 times daily with meals. The main downside: significant GI side effects — nausea, diarrhea, stomach cramps — especially early on. Up to 20–30% of patients have enough GI distress that they stop taking it. **Metformin XR (extended-release):** Same drug, slower release. The extended coating dissolves gradually in the GI tract, which means the medication is absorbed more slowly and with less concentration at any one point. Result: significantly fewer GI side effects. Key point: immediate-release and XR metformin have the same blood sugar lowering effect. It's a tolerability upgrade, not an efficacy upgrade. **When to use XR:** Most doctors start with regular metformin (cheaper, often better covered), then switch to XR if GI side effects are intolerable. Some doctors start directly with XR — especially in older patients or those with sensitive stomachs. **Generic cost:** Regular metformin: under $10/month. Metformin XR generic: $15–$30/month. Both are among the most affordable diabetes medications available. **Important note:** Generic metformin XR recalls have occurred in past years (2020 NDMA contamination). Check FDA recall lists if you're filling a generic prescription, and ask your pharmacist about the manufacturer. Major branded generics (e.g., Glumetza) have not been involved in recalls. **Take it with food.** Always. Even XR causes GI issues when taken on an empty stomach.
Read original source
NIH
October 1, 2025
Farxiga (Dapagliflozin) Guide: Diabetes, Heart Failure, and Kidney Disease
Farxiga (dapagliflozin) is an SGLT2 inhibitor made by AstraZeneca. Like Jardiance, it lowers blood sugar by causing kidneys to excrete glucose. But it's earned a place in cardiology and nephrology for three separate FDA approvals: type 2 diabetes, heart failure, and chronic kidney disease — the broadest label of any SGLT2 inhibitor. **Blood sugar lowering in diabetes:** A1C reductions of 0.5–1.0%. Weight loss of 3–6 lbs. Blood pressure reduction of 2–4 mmHg systolic. These effects are modest compared to GLP-1s, but Farxiga is often used in combination with a GLP-1 or metformin for additive benefit. **Heart failure:** The DAPA-HF trial enrolled 4,744 patients with heart failure with reduced ejection fraction (HFrEF) — regardless of whether they had diabetes. Farxiga reduced the combined risk of worsening heart failure or cardiovascular death by 26%. This was a landmark result: a diabetes drug helping non-diabetic heart failure patients. **Chronic kidney disease:** The DAPA-CKD trial enrolled patients with CKD stages 2–4, with or without diabetes. Farxiga reduced the risk of kidney function decline, dialysis, kidney transplant, or death from kidney/cardiovascular causes by 39%. It was so effective the trial was stopped early. Now FDA-approved for CKD. **Doses:** 5 mg/day (starting) or 10 mg/day. Taken once daily by mouth. **Side effects:** Same as Jardiance — yeast infections, UTIs, rare DKA risk. Avoid in severe kidney impairment (eGFR < 25 for CKD indication; check with doctor for diabetes use). **Generic availability:** As of 2025, dapagliflozin has generic versions entering the market in some regions — significantly cutting the cost. Ask your pharmacist about availability. **Who benefits most:** Patients with type 2 diabetes plus heart failure or CKD, who would benefit from addressing all three conditions simultaneously.
Read original source
NIH
September 15, 2025
Jardiance (Empagliflozin) for Type 2 Diabetes and Heart Failure: Full Guide
Jardiance belongs to the SGLT2 inhibitor class — a different mechanism from GLP-1 drugs. Instead of affecting hormones, it works directly on your kidneys, blocking them from reabsorbing glucose and causing you to urinate out excess sugar. It's one of the most important diabetes drugs of the past decade because of proven heart and kidney protection. **How it works:** The SGLT2 transporter in your kidneys reabsorbs about 90% of the glucose that gets filtered. Empagliflozin blocks it. Result: 60–90 grams of glucose excreted in urine per day. Your blood sugar drops, you lose a few pounds from the calorie loss, blood pressure drops slightly (from the sodium loss), and pressure in the kidneys decreases. **Blood sugar lowering:** A1C reduction of 0.5–1.0% — moderate compared to GLP-1s, but meaningful as add-on therapy. **Where it really shines — heart protection:** The EMPA-REG OUTCOME trial changed cardiology practice. In patients with type 2 diabetes and established cardiovascular disease, Jardiance reduced: cardiovascular death by 38%, heart failure hospitalization by 35%, and worsening kidney disease by 46%. No other diabetes drug at the time had such strong data. **Heart failure indication:** Jardiance is also FDA-approved to reduce hospitalization risk in adults with heart failure (HF) — with or without diabetes. It's now standard of care for HFrEF (reduced ejection fraction). **Side effects:** Genital yeast infections (more common in women), urinary tract infections, and a rare but serious condition called diabetic ketoacidosis (DKA) — even at normal blood sugar levels. Stay well hydrated. Stop Jardiance before any surgery. **Dose:** 10 mg/day (standard), 25 mg/day (kidney/heart protection). Taken by mouth once daily, with or without food. **Cost:** ~$600/month list price. AstraZeneca and Boehringer Ingelheim offer copay assistance. Generic dapagliflozin (Farxiga) is now available — worth discussing with your doctor.
Read original source
NIH
August 1, 2025
Trulicity (Dulaglutide) for Type 2 Diabetes: Complete Guide
Trulicity is a once-weekly injectable GLP-1 receptor agonist made by Eli Lilly. It was one of the first GLP-1 medications approved for type 2 diabetes and remains widely prescribed because of its ease of use, proven heart protection, and reliable blood sugar lowering. **How it works:** Like Ozempic and Mounjaro, Trulicity mimics the GLP-1 gut hormone. It tells your pancreas to release insulin when blood sugar is high, slows stomach emptying, and reduces appetite. It doesn't cause low blood sugar on its own (only when combined with sulfonylureas or insulin). **How well does it work?** The AWARD trials showed A1C reductions of 0.7–1.4% depending on dose. The REWIND cardiovascular outcomes trial — 9,901 patients followed for 5+ years — found Trulicity reduced major adverse cardiovascular events (MACE) by 12% in patients with or at high risk for heart disease. This makes it one of the few diabetes drugs with proven heart protection at scale. **Doses:** 0.75 mg/week (starting), 1.5 mg/week (standard maintenance), 3.0 mg/week, 4.5 mg/week (maximum). Trulicity comes in a unique autoinjector pen that hides the needle — many patients who are needle-averse find this design less intimidating than other GLP-1 pens. **Weight loss:** Modest — typically 3–7 lbs over a year. Less than Ozempic or Mounjaro, but for patients whose primary goal is blood sugar control (not weight loss), this is often adequate. **Side effects:** Nausea, diarrhea, vomiting (usually mild and transient). Fewer reports of severe nausea than higher-dose semaglutide. Same thyroid cancer and pancreatitis warning as all GLP-1s. **Who is it best for?** Patients with cardiovascular disease or high cardiovascular risk who want a well-established GLP-1 with strong heart outcome data, or those with needle phobia who prefer the autoinjector design. **Cost:** ~$900/month list price. Eli Lilly copay card brings it to $25/month for most commercially insured patients.
Read original source
NIH
November 15, 2025
Ozempic vs. Mounjaro for Type 2 Diabetes 2026: Which Is Better?
Ozempic (semaglutide) and Mounjaro (tirzepatide) are two of the most powerful diabetes medications available today. Both are weekly injections, both lower blood sugar significantly, and both cause weight loss — but there are important differences. Here's how they compare on the metrics that matter most. **Blood sugar reduction (A1C):** - Ozempic (1 mg): ~1.5% A1C reduction - Ozempic (2 mg): ~1.7% A1C reduction - Mounjaro (10 mg): ~2.2% A1C reduction - Mounjaro (15 mg): ~2.5% A1C reduction Mounjaro wins by a meaningful margin — especially at higher doses. **Weight loss:** - Ozempic 2 mg: average 13–14 lbs (6.2% body weight) - Mounjaro 15 mg: average 25–27 lbs (11.2% body weight) Mounjaro produces roughly twice the weight loss of Ozempic. **Head-to-head data:** The SURPASS-2 trial directly compared Mounjaro to Ozempic 1 mg. At every Mounjaro dose tested, both A1C reduction and weight loss were superior. Mounjaro 15 mg vs. Ozempic 1 mg: A1C −2.46% vs. −1.86%; weight loss −12.4 lbs vs. −6.2 lbs. **Cardiovascular outcomes:** Ozempic has the longer track record — the SUSTAIN-6 trial proved heart protection in high-risk patients (26% reduction in major cardiac events). Mounjaro's SURPASS-CVOT results show cardiovascular benefit too, and the SURMOUNT program continues to expand the data. **Side effects:** Both have similar GI side effects (nausea, vomiting, diarrhea). Mounjaro may have slightly more nausea at higher doses due to GIP activity. **Cost:** Both are in the $950–$1,100/month range list price. Insured patients typically pay $25–$50/month with manufacturer copay cards. **Which to choose:** If your top priority is maximum A1C and weight reduction and your insurance covers it, Mounjaro is generally the stronger option. If you've been on Ozempic and doing well, there may be no reason to switch. Talk to your doctor about your individual cardiovascular risk, weight goals, and insurance coverage.
Read original source
NIH
October 1, 2025
Mounjaro (Tirzepatide) for Type 2 Diabetes: The Dual-Action Drug Explained
Mounjaro is the first FDA-approved medication that activates two gut hormone receptors at once — GLP-1 and GIP. That dual action makes it the most effective glucose-lowering injection currently on the market, and it produces substantially more weight loss than GLP-1s alone. **How it works:** GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both released after eating and work together to boost insulin release, suppress glucagon, slow stomach emptying, and reduce appetite. Activating both pathways amplifies the effect significantly. **How well does it work?** The SURPASS trials compared Mounjaro directly to other leading diabetes drugs. At 15 mg (max dose): A1C dropped by up to 2.6% — the largest reduction ever seen in a phase 3 trial. Weight loss averaged 21 lbs (at 5 mg) to 27 lbs (at 15 mg) — roughly 10–12% of body weight. In a head-to-head trial against semaglutide 1 mg (Ozempic), Mounjaro produced significantly greater A1C and weight reductions. **Doses:** 2.5 mg/week (starting, 4 weeks only) → 5 mg/week → 7.5 mg/week → 10 mg/week → 12.5 mg/week → 15 mg/week. Most patients settle at 5–10 mg for good glycemic control. **Side effects:** Similar to Ozempic — nausea, diarrhea, constipation. Generally well-tolerated; slow dose escalation minimizes early GI issues. Same thyroid cancer warning as GLP-1s (theoretical, animal data only). **Zepbound vs. Mounjaro:** Same tirzepatide molecule. Zepbound is the weight-loss brand (approved at higher doses); Mounjaro is the diabetes brand. **Cost:** About $1,070/month list price. Eli Lilly's Lilly Insulin Value Program and copay assistance cards apply — see the drug savings article for how to access them.
Read original source
NIH
September 1, 2025
Ozempic (Semaglutide) for Type 2 Diabetes: What You Need to Know in 2026
Ozempic is a once-weekly injectable medication approved by the FDA to lower blood sugar in adults with type 2 diabetes. Its active ingredient — semaglutide — belongs to the GLP-1 receptor agonist class. It works by mimicking a hormone your gut releases after eating, which tells your pancreas to release insulin and signals your brain that you're full. **How well does it work?** In clinical trials, Ozempic lowered A1C by 1.0–1.8% depending on dose. Most people also lose weight — an average of 10–15 lbs over a year — which is a significant added benefit for the majority of type 2 diabetes patients. The SUSTAIN trials showed it also reduced the risk of major cardiovascular events (heart attack, stroke) by 26% in high-risk patients. **Doses and how to use it:** Ozempic comes in prefilled pens: 0.5 mg/week (starting dose), 1 mg/week (maintenance), and 2 mg/week (maximum). You inject it once a week under the skin of your stomach, thigh, or upper arm. The day of the week doesn't matter — pick one and stick with it. **Side effects to know:** The most common are nausea, vomiting, and diarrhea, especially in the first few weeks. These usually improve over time. Starting at 0.5 mg and going up slowly helps. Rare but serious risks include pancreatitis and — in people with a personal or family history of a specific thyroid cancer (MTC) — a theoretical thyroid tumor risk (based on animal studies; not confirmed in humans). **Ozempic vs. Wegovy:** Same molecule, different doses. Wegovy (2.4 mg/week) is FDA-approved specifically for weight loss. Ozempic tops out at 2 mg/week for diabetes. **Cost:** About $935/month list price without insurance. Most insured patients pay significantly less. Novo Nordisk's Patient Assistance Program covers eligible patients with no insurance or low income. See the drug savings section for details.
Read original source
Clinical Trial
March 20, 2026
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Researchers are working to understand why some people with diabetes develop kidney problems while others do
Read original source
Clinical Trial
March 20, 2026
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Managing your weight is one of the most effective ways to keep your blood
Read original source
Clinical Trial
March 20, 2026
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Researchers are exploring a new medicine called eloralintide that may help you manage
Read original source🍽️ Diabetes-Friendly Recipes
See recipes designed to work alongside Diabetes management — each cross-checked against our medication interaction database.
About this content
Sourced from U.S. government health agencies (NIH, CDC, FDA) and ClinicalTrials.gov. Summaries are written in plain English. Always consult your doctor before making healthcare decisions. My Sugar Pill does not provide medical advice.
About My Sugar Pill · No sponsored content · No data selling · Free, always.